pegfilgrastim – Apothera

In Stock: Fulphila (Pegfilgrastim-jmdb, Biosimilar of Neulasta) 6mg/0.6mL Syringe

By ApoThera May 1, 2023Blog

In Stock: Fulphila (Pegfilgrastim-jmdb, Biosimilar of Neulasta) 6mg/0.6mL Syringe (Click Here) Prevention of Chemotherapy-Induced Neutropenia – 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion…

In Stock: Neulasta Biosimilar (Fulphila, Pegfilgrastim-jmdb) 6mg/0.6mL Syringe

By ApoThera April 2, 2023Blog

In Stock: Neulasta Biosimilar (Fulphila, Pegfilgrastim-jmdb) 6mg/0.6mL (Click Here) Prevention of Chemotherapy-Induced Neutropenia – 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy…

In Stock: Pegfilgrastim-jmdb (Fulphila, Biosimilar to Neulasta) 6mg/0.6mL Syringe

By ApoThera March 29, 2023Blog

In Stock: Fulphila Biosimilar to Neulasta (Pegfilgrastim-jmdb) 6mg/0.6mL Syringe (Click Here) Prevention of Chemotherapy-Induced Neutropenia – 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion…

FDA Approves Fylnetra (pegfilgrastim-pbbk), Biosimilar to Neulasta (pegfilgrastim), for Treating Neutropenia

By ApoThera June 12, 2022Blog

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a…